Roche Holding : Normalisation of activity but top line growth still too weak
>Q3: return to normal underway after the dip in Q2 - Roche is on the road to recovery in Q3. Indeed, Q3 sales were up slightly (1% excluding forex effects) after Q2 (-4%) with far fewer non-COVID patients in the hospitals. The group has yet to return to the growth levels seen in Q1 (+7%) but we think the recovery should continue in Q4 and we forecast +5% for the last three months of the year. We think that the performance will be driven by a return to a better level o...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.